iShares Nasdaq Biotechnology Index Fund ETF News

Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.

The biotechnology sector has disappointed overall; we think there are better ways to get exposure to the healthcare sector. iShares Biotechnology ETF has underperformed relative to Health Care Select

Biotechnology has traded basically sideways since the start of 2023. In the face of higher rates, stronger dollar, inflation, FDA approvals and busts, and an emerging winter season, the ETF IBB has a

The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.

The events of the last few years have made biotech investing look easier than it is. But, investing in biotech is not for the faint of heart.

ETFs can be an easy, powerful way to diversify your stock holdings. While there are dozens of options, Ark Innovation, iShares Biotechnology, and Vanguard 500 Index Fund are three ETFs that should shi

The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.

Shares of PaxMedia Inc. PXMD, -11.91% bounced 2.0% in premarket trading Thursday, after the biopharmaceutical company, which focuses on treatments of Autism Spectrum Disorder (ASD) said it was not awa

Let's explore the burgeoning world of FemTech, a sector dedicated to women's health, and discover why it's a lucrative investment opportunity.

Biotech stocks have been largely out of relative favor in 2023. Amid possible market mean reversion and seasonal tailwinds, IBB's low P/E is a positive attribute. But poor absolute price action and re

The iShares Biotechnology ETF NASDAQ: IBB has recently shown signs of potential consolidation leading to a breakout. Such price action and development should prompt investors to notice possible shifts

The US private domestic sector balance increased by $130bn in May 2023, a positive result driven by a $246bn injection of funds from the federal government. Bank credit creation retraction continued f

Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.